Therapeutic intervention and signaling

Current Opinion in Cell Biology

Volumn 10, Issue 2, 1998, Pages 284-288

  Heimbrook, David C ^a   Oliff, Allen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GERANYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN;

APOPTOSIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0032054248     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80152-X     Document Type: Article

References (40)

1. Heimbrook DC, Oliff A, Gibbs JB. Essentials of signal transduction. DeVita V, Hellman S, Rosenberg S. edn 5 Cancer Principles and Practice of Oncology. 1997;35-43 Lippincott-Raven Press, Philadelphia, PA.
2. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem. 62:1993;851-891.
3. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
4. Kohl NE, Oliff A, Gibbs JB. Farnesyl transferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
5. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260:1993;1937-1942.
6. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
7. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms J, Giuliani EA, Gomez RP, Graham SL, Hamilton K, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1:1995;792-797.
8. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem. 270:1995;6221-6226.
9. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. of special interest J Biol Chem. 272:1997;14459-14464 A quantitative examination of the prenylation patterns of Ras proteins in intact cells. The study clearly shows that geranylgeranylation of N- and K-Ras is dramatically enhanced if the farnesylation pathway is inhibited.
10. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem. 272:1997;14093-14097.
11. Cox AD, Hisaka MM, Buss JE, Der CJ. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol. 12:1992;2606-2615.
12. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, et al. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem. 272:1997;10232-10239.
13. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS. Crystal structure of protein farnesyltransferase at 2.25 Å resolution. of special interest Science. 275:1997;1800-1804 Resolution of the crystal structure of FTase at 2.25 Å reveals the zinc binding site at the juncture of two clefts that appear to bind the reaction substrates.
14. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 89:1992;6403-6407.
15. Boyartchuk VL, Ashby MN, Rine J. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. of special interest Science. 275:1997;1796-1800 The RCE1 and AFC1 genes encodes proteases which appear to be responsible for processing of prenylated proteins in yeast. Inactivation of RCE1 causes defects in Ras localization and suppresses Ras activity.
16. Kawada M, Fukazawa H, Mizuno S, Uehara Y. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras. Biochem Biophys Res Comm. 231:1997;735-737.
17. Scherr M, Grez M, Ganser A, Engels JW. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. J Biol Chem. 272:1997;14304-14313.
18. White MA, Nicoletter C, Minden A, Polverino A, van Aelst L, Karin M, Wigler MH. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-541.
19. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, van Aelst L, Wigler MH, Der CJ. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol. 16:1996;3923-3933.
20. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci USA. 92:1995;11781-11785.
21. Qiu RG, Chen J, Kirn D, McCormick D, Symons M. An essential role for Rac in Ras transformation. Nature. 374:1995;457-459.
22. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors after the prenylation and growth-stimulating function of RhoB. of outstanding interest J Biol Chem. 272:1997;15591-15594 The critical biological targets of farnesyltransferase inhibitors remains an area of controversy in this field. Clearly these drugs are not simply anti-Ras agents. RhoB has always been one of the leading alternate candidates for mediating the effects of FTase inhibitors. This paper now shows that these drugs can specifically antagonize the growth enhancing properties of RhoB.
23. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem. 272:1997;10608-10615.
24. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med. 2:1996;675-688.
25. Monia BP. First and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anti-Cancer Drug Design. 12:1997;327-339.
26. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 92:1995;7686-7689.
27. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 275:1997;1649-1652.
28. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. of special interest Trends Biol Sci. 22:1997;267-272 A concise but thorough review of the PI 3-K field.
29. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 370:1994;527-532.
30. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. of special interest Cell. 89:1997;457-467 The data presented in this manuscript suggest that PI 3-K is necessary for Ras-induced membrane ruffling, and this pathway is required for efficient Ras-dependent transformation, PI 3-K activity is also shown to be sufficient to cause membrane ruffling, and this activity is mediated by Rac.
31. Burgering BM, Coffer PJ. Protein Kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 376:1995;599-602.
32. Salim K, Bottomley MJ, Querfurth E, Zvelebil MJ, Gout I, Scaife R, Margolis RL, Gigg R, Smith CI, Driscoll PC, et al. Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. of special interest EMBO J. 15:1996;6241-6250 These studies demonstrate that different PH domains bind to liposomes containing different phosphoinositides with distinct specificities.
33. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream of AKTion blocks apoptosis. Cell. 88:1997;435-437.
34. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 275:1997;665-668.
35. Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. of outstanding interest Science. 277:1997;567-570 See annotation to [37].
36. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B-alpha. of outstanding interest Curr Biol. 7:1997;261-269 These two references [36,37] characterize the phosphoinositide-activated Akt kinase(s) responsible for phosphorylation of residue Thr308 of Akt.
37. Hemmings BA. Ptdlns(3,4,5)P3 gets its message across. Science. 277:1997;534.
38. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 3:1997;614-620.
39. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. of outstanding interest Science. 278:1997;687-689 The pro-apoptotic activity of the bcl-2 homolog, BAD, is inhibited by phosphorylation at specific serine residues. The data in this manuscript demonstrate that active Akt phosphorylates BAD on these specific serines in response to growth factor stimulation of intact cells.
40. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:1997;661-665.